Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis - PubMed
3 hours ago
- #systematic review
- #acute myeloid leukemia
- #menin inhibitors
- Menin inhibitors show promise for relapsed/refractory AML, especially in NPM1-mutated and KMT2A-rearranged cases.
- The pooled overall response rate across 14 studies (784 patients) was 54.6%, with a complete response rate of 29.3%.
- Combination therapy with hypomethylating agents and venetoclax significantly improved complete response rates compared to monotherapy.
- Common adverse events included liver function test elevation (38.7%), febrile neutropenia (33.6%), and diarrhea (28.8%).
- Treatment-related mortality was 5.0%, with differentiation syndrome occurring in 14.6% of cases.